A5013149137- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Autoimmune and Inflammatory Disorders Research
- Acute Myeloid Leukemia Research
- Nausea and vomiting management
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune Cell Function and Interaction
- Blood groups and transfusion
- Cancer therapeutics and mechanisms
- Antifungal resistance and susceptibility
- Herpesvirus Infections and Treatments
- DNA Repair Mechanisms
- Chronic Myeloid Leukemia Treatments
- Fungal Infections and Studies
- Hemoglobinopathies and Related Disorders
- Chronic Lymphocytic Leukemia Research
- T-cell and Retrovirus Studies
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- Antibiotics Pharmacokinetics and Efficacy
- Toxoplasma gondii Research Studies
- Renal Transplantation Outcomes and Treatments
Memorial Sloan Kettering Cancer Center
2022-2024
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent who received following hematopoietic cell transplantation. No developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious preventing infections.
Isavuconazonium sulfate (ISA) is a triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis in adults. This single-center, retrospective review pediatric oncology stem cell transplant patients receiving ISA prophylaxis (n=20) or (n=6) fungal disease (IFD) aims to characterize real-world clinical efficacy toxicity <18 years age. Of 20 prophylaxis, three had presumed breakthrough IFD (1 proven, 2 probable/possible). No adverse effects were attributed use led...
Busulfan is an alkylating drug routinely used in conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT). A myeloablative regimen, including busulfan, commonly patients undergoing T-cell depletion (TCD) and allo-HCT, but data on optimal busulfan pharmacokinetic (PK) exposure this setting are limited. Between 2012 2019, PK was performed to target area under the curve between 55 66 mg × h/L over 3 days using a noncompartmental analysis model. We retrospectively...